Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH)

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH) is focused on developing a proprietary class of adrenal steroid hormones as innovative pharmaceuticals for human health. Through its Hormonal Signaling Technology Platform, the company is developing a new series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands from the body’s most abundant circulating adrenal steroid. For further information, visit the Company’s web site at www.holliseden.com.